At ProQR, we are dedicated to improving the lives of patients and families affected by rare and common disorders using Axiomer, our innovative RNA editing platform technology.
At ProQR, our mission is to edit RNA, treat disease and change lives. This guides every decision we make as we work to develop new treatment options for people living with high unmet need.
Our vision is to create a world where genetics informs your health - but never limit it. By harnessing the power of RNA editing, we strive to make our vision for the future a reality.
ProQR's leadership is a strong team with proven track record. Find out who is on our management team, board of directors and scientific advisory board.
… in Cambridge, Massachusetts, USA, developing innovative RNA-editing medicines through its proprietary Axiomer™ … strategy, provide medical leadership and advance RNA-editing therapies from concept to clinical evidence. We … shape early clinical-development strategy and help advance RNA-editing therapies for patients. You will combine hands-on …
On March 29, 2023 ProQR will host a virtual R&D event to showcase its proprietary Axiomer RNA-editing technology platform. ProQR will also announce initial pipeline targets for internal development.
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
ProQR will host a virtual Investor and Analyst Event highlighting its pipeline entitled:
“Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810”